We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Urine-Based Test Improves Detection of Prostate Cancer

By LabMedica International staff writers
Posted on 01 Jun 2015
A new urine-based test improved prostate cancer detection, including detecting more aggressive forms of prostate cancer, compared to traditional models based on prostate serum antigen, or PSA, levels. More...


The test reports individual risk estimates for prostate cancer (PCa) and high grade cancer and each patient's personal threshold for choosing to undergo biopsy may vary, so there is no single cutoff for a "positive" result.

A team of scientists led by those at the University of Michigan Medical School (Ann Arbor, MI, USA) developed the test, which they called Mi-Prostate Score, or MiPS. It combines PSA with two markers for prostate cancer, transmembrane protease, serine 2: V-ets avian erythroblastosis virus E26 oncogene homolog (T2:ERG) and prostate cancer antigen 3 (PCA3), both of which can be detected in a urine sample.

The team studied a total of 1,977 men who were undergoing prostate biopsy because of elevated PSA levels. Using urine samples, the team conducted MiPS testing and compared results to various combinations of PSA, PCA3, T2:ERG and other PSA-based risk calculators. They assessed how well the individual biomarkers and combinations of biomarkers predicted the likelihood of cancer and the likelihood of high-risk cancer, the aggressive type that needs immediate treatment.

Among informative validation cohort samples from 1,225 men, 80% from patients presenting for initial biopsy, models incorporating T2: ERG had significantly greater area under the curve (AUC) than PSA or multivariate Prostate Cancer Prevention Trial risk calculator version (PCPTrc) for predicting or high-grade PCa (Gleason score greater than 6) on biopsy. MiPS models incorporating T2:ERG score had significantly greater AUC than models incorporating only PCA3 plus PSA (or PCPTrc or high-grade cancer PCPTrc [PCPThg]).

Scott A. Tomlins, MD, PhD, assistant professor of pathology and urology and lead author of the study said, “Around 50% of men who undergo a prostate biopsy will not have cancer. We need better ways to manage elevated PSA and determine who really needs to have a biopsy. MiPS gives men and their doctors better information to help make those decisions.” The study was published on May 16, 2015, in the journal European Urology.

Related Links:

University of Michigan Medical School



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.